REPEAT: Seeing Machines loss narrows; Hansard profit falls
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
| Price | 80.50p on 09-12-2025 at 18:35:05 |
|---|---|
| Change | 1.50p 1.9% |
| Buy | 85.00p |
| Sell | 76.00p |
| Last Trade: | Sell 910.00 at 77.50p |
| Day's Volume: | 115,410 |
| Last Close: | 80.50p |
| Open: | 79.50p |
| ISIN: | GB00BMWLM973 |
| Day's Range | 80.00p - 80.50p |
| 52wk Range: | 35.40p - 97.50p |
| Market Capitalisation: | £30.39m |
| VWAP: | 80.62914p |
| Shares in Issue: | 37.76m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Arecor Therape (AREC) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 910 | 77.50p | Ordinary |
15:57:24 - 09-Dec-25 |
| Unknown* | 10,000 | 81.60p | Ordinary |
15:34:07 - 09-Dec-25 |
| Buy* | 79 | 81.70p | Ordinary |
14:13:27 - 09-Dec-25 |
| Sell* | 61,421 | 80.00p | Uncrossing Trade |
11:00:13 - 09-Dec-25 |
| Unknown* | 10,000 | 81.95p | Ordinary |
10:17:51 - 09-Dec-25 |
| Buy* | 7,000 | 82.00p | Ordinary |
09:37:33 - 09-Dec-25 |
| Buy* | 6,000 | 82.00p | Ordinary |
09:26:04 - 09-Dec-25 |
| Sell* | 15,000 | 80.00p | Uncrossing Trade |
09:00:22 - 09-Dec-25 |
| Unknown* | 0 | 76.00p | SI Trade |
08:01:18 - 09-Dec-25 |
| Buy* | 5,000 | 82.65p | Ordinary |
08:01:09 - 09-Dec-25 |
Arecor Therape (AREC) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 9th Dec 2025 7:00 am | RNS | Arecor and Sequel Med Tech to host fireside panel |
| 17th Nov 2025 11:37 am | RNS | Holding(s) in Company |
| 11th Nov 2025 9:50 am | RNS | Holding(s) in Company |
| 4th Nov 2025 7:00 am | RNS | Enhanced IP Coverage: AT278 & Oral Peptide Program |
| 29th Sep 2025 7:00 am | RNS | Directorate Changes |
| 25th Sep 2025 7:00 am | RNS | Interim results for the six months to 30 June 2025 |
| 25th Sep 2025 7:00 am | RNS | Co-Development Agreement & Monetisation Deal |
| 24th Sep 2025 9:30 am | RNS | Notice of Interim Results |
| 4th Sep 2025 7:00 am | RNS | Positive FDA Feedback on Phase 2 Study Design |
| 28th Aug 2025 12:00 pm | RNS | Holding(s) in Company |